Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$27.31 USD
+2.29 (9.15%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $27.24 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Enliven Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -71.58 | 1.49 | -51.38 | -41.36 | -23.46 |
Depreciation/Amortization & Depletion | -4.31 | 0.72 | 0.25 | 0.22 | 0.01 |
Net Change from Assets/Liabilities | 1.40 | -5.36 | 0.51 | 1.51 | 0.67 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 13.22 | -32.42 | 3.85 | 2.23 | 0.90 |
Net Cash From Operating Activities | -61.27 | -35.57 | -46.77 | -37.40 | -21.88 |
Property & Equipment | -0.15 | 34.64 | -0.01 | -0.02 | -0.14 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -148.26 | 41.88 | -1.62 | -16.70 | -23.92 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -148.41 | 76.52 | -1.63 | -16.72 | -24.06 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.40 | 0.00 | 0.86 | 98.60 | 45.58 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 47.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 233.89 | -1.23 | 1.24 | -1.72 | -2.00 |
Net Cash from Financing Activities | 234.29 | -1.23 | 49.10 | 96.88 | 43.58 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 24.61 | 39.71 | 0.70 | 42.76 | -2.36 |
Cash at Beginning of Period | 75.59 | 48.48 | 47.79 | 5.02 | 7.38 |
Cash at End of Period | 100.20 | 88.20 | 48.48 | 47.79 | 5.02 |
Diluted Net EPS | -2.01 | 0.24 | -9.48 | -14.12 | NA |
Fiscal Year End for Enliven Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -22.74 | -71.58 | -52.21 | -31.45 |
Depreciation/Amortization & Depletion | NA | -0.58 | -4.31 | -2.60 | -0.69 |
Net Change from Assets/Liabilities | NA | -4.64 | 1.40 | -4.06 | -7.22 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 4.59 | 13.22 | 10.09 | 6.46 |
Net Cash From Operating Activities | NA | -23.36 | -61.27 | -48.79 | -32.89 |
Property & Equipment | NA | -0.02 | -0.15 | -0.14 | -0.12 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -17.87 | -148.26 | -186.96 | -151.43 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -17.89 | -148.41 | -187.10 | -151.55 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 90.27 | 0.40 | 0.31 | 0.28 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 233.89 | 233.89 | 234.34 |
Net Cash from Financing Activities | NA | 90.27 | 234.29 | 234.20 | 234.62 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 49.02 | 24.61 | -1.69 | 50.18 |
Cash at Beginning of Period | NA | 100.20 | 75.59 | 75.59 | 75.59 |
Cash at End of Period | NA | 149.22 | 100.20 | 73.90 | 125.77 |
Diluted Net EPS | NA | -0.54 | -0.29 | -0.51 | -0.41 |